Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding.

Trial Profile

Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 13 Sep 2013 Primary endpoint 'Viral-load' has not been met according to results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 25 Jul 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top